Last edited by Gacage
Saturday, May 9, 2020 | History

4 edition of An economic evaluation of clopidogrel in patients with vascular disease found in the catalog.

An economic evaluation of clopidogrel in patients with vascular disease

Chau Tran

An economic evaluation of clopidogrel in patients with vascular disease

by Chau Tran

  • 315 Want to read
  • 22 Currently reading

Published by National Library of Canada in Ottawa .
Written in English


Edition Notes

Thesis (M.Sc.) -- University of Toronto, 1999.

SeriesCanadian theses = -- Thèses canadiennes
The Physical Object
FormatMicroform
Pagination2 microfiches : negative. --
ID Numbers
Open LibraryOL22332980M
ISBN 100612458598
OCLC/WorldCa47270104

  Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of clopidogrel was associated with a modest but statistically significant advantage over aspirin in reducing adverse cardiovascular outcomes in patients with established cardiovascular disease in the CAPRIE trial. pcv31 economic evaluation of clopidogrel in secondary prevention of atherothrombotic events in hungary Article in Value in Health 6(6) December with 3 Reads How we measure 'reads'.

The 11 economic evaluations included in the review of cost-effectiveness indicated that for patients with previous peripheral arterial disease, ischaemic stroke or MI, clopidogrel is cost. Infants with systemic-to-pulmonary-artery shunts were assigned to clopidogrel or placebo in addition to usual therapy (including aspirin in 88% of patients). Death, heart transplantation, shunt thr Cited by:

  Antiplatelet therapy is universally recommended for the prevention of recurrent events in patients with noncardioembolic ischaemic stroke or transient ischaemic attack (TIA), acute and chronic coronary artery disease, or peripheral arterial disease. However, choosing which antiplatelet agents to use in these situations remains controversial. The use of aspirin, aspirin plus extended-release Cited by: 4. Strategies for Incorporating Resource Allocation and Economic Panels should include one or more members with expertise in economic evaluation and should mandate that those members lead the group in consideration of resource allocation issues. for secondary prevention in coronary artery disease and other vascular diseases (clopidogrel vs Cited by:


Share this book
You might also like
Granadas Manchester plays

Granadas Manchester plays

Dirty Magic

Dirty Magic

Time-dependent Hartree-Fock calculations of the scattering of Kr-ions from p208sPb, p209sBi, and p139sLa / K. T. R. Davies

Time-dependent Hartree-Fock calculations of the scattering of Kr-ions from p208sPb, p209sBi, and p139sLa / K. T. R. Davies

The Spirit and the form

The Spirit and the form

Go and Have a Good Time

Go and Have a Good Time

Masterpieces from the National Gallery of Ireland

Masterpieces from the National Gallery of Ireland

Russian elegance

Russian elegance

I remember, book II

I remember, book II

Ske Sound Engineer Home Study Course

Ske Sound Engineer Home Study Course

Torah

Torah

An economic evaluation of clopidogrel in patients with vascular disease by Chau Tran Download PDF EPUB FB2

An economic evaluation was undertaken to estimate costs and survival outcomes with clopidogrel, a novel antiplatelet vs comparator drug treatment in patients with ischemic stroke (IS), myocardial infarction (MI) or peripherai arterial disease (PAD).Author: Chau Tran.

The 11 economic evaluations included in the review of cost-effectiveness indicated that for patients with previous peripheral arterial disease, ischaemic stroke or MI, clopidogrel is cost-effective compared with ASA, and for patients with previous ischaemic stroke/TIA, treatment with MRD + ASA is cost-effective compared with any other treatment in patients in the secondary prevention of occlusive vascular Cited by:   Background: Current guidelines recommend treatment with antiplatelet and anticoagulant therapy for the secondary prevention of atherothrombotic events among patients with non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina (UA).

The CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) trial has shown that clopidogrel alone or in combination with Cited by: 6.

The economic evaluation showed that, for patients undergoing PCI at one year of dual antiplatelet therapy with ticlopidine and ASA, followed by lifetime ASA, may be a more cost-effective treatment (compared with clopidogrel plus ASA, and ASA monotherapy Cited by: 1.

Interpretation: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke. Antiplatelet therapy in some form is required in all patients with vascular disease.

Clopidogrel in patients with PAD is a critically important therapy, particularly in the higher risk patients. Clopidogrel carries the only FDA-labeled indication for cardiovascular risk reduction in patients Cited by: Background — Clopidogrel is one of the most commonly prescribed medications because of its ability to improve clinical outcomes for a broad range of cardiovascular conditions.

After patent protection expired for Plavix inmany healthcare systems adopted generic clopidogrel as a strategy to reduce healthcare costs. assessed the cardiovascular benefit and safety of clopidogrel hydrogen sulphate in comparison to aspirin (ASA) in patients with cardiovascular disease whose qualifying ischaemic event (MI, stroke, or PAD) was a manifestation of disease in one or more vascular beds.

Evidence suggests that those patients who suffer an MI are at greater. BACKGROUND Pharmacogenetic determinants of the response of patients to clopidogrel contribute to variability in the biologic antiplatelet activity of the drug.

The effect of these determinants on clinical outcomes after an acute myocardial infarction is unknown. METHODS We consecutively enrolled patients presenting with an acute myocardial infarction in a nationwide French registry and.

An economic evaluation was then conducted to determine the cost-effectiveness of clopidogrel, ASA, or ASA plus clopidogrel for the management of patients with ACS and patients with PVD.

The budgetary impacts of potential changes in clopidogrel and ASA use were assessed based on historical prescribing patterns and market shares of antiplatelet drugs for ACS and PVD indications. Indications. Clopidogrel is FDA approved for the medical management of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI) in patients receiving fibrinolytic therapy, and for secondary prevention in recent myocardial infarction (MI), recent stroke, and peripheral arterial disease.

The economic consequences of non–evidence-based clopidogrel use Niteesh K. Choudhry, MD, PhD, Raisa Levin, MS, and Jerry Avorn, MD Boston, MA Background Clinical trials have helped clarify the efficacy of clopidogrel for the treatment and prevention of vascular disease.

Clopidogrel is more effective than aspirin in preventing recurrent vascular events, but concerns about its cost-effectiveness have limited its use. We evaluated the cost-effectiveness of clopidogrel and aspirin as secondary prevention in patients with a prior myocardial infarction, a prior stroke, or peripheral arterial by: Clopidogrel was a cost-effective alternative to aspirin for the secondary prevention of vascular events in patients with peripheral vascular disease or recent stroke, and the cost per quality-adjusted life-year (QALY) fell within traditional thresholds for cost-effectiveness.

Approximately 5–40 % of patients treated with clopidogrel do not display an adequate antiplatelet response. Clopidogrel resistance may be caused by insufficient drug absorption or impaired metabolic activation of the drug. The aim of this study was to evaluate the pharmacokinetics of clopidogrel and its metabolites in plasma samples from patients treated with high and low doses of Cited by: A systematic review was conducted of economic evaluations that compared the use of clopidogrel with other antiplatelet therapies for the management of stroke patients.

An economic evaluation was done to determine the cost-effectiveness of clopidogrel, ASA, ASA plus clopidogrel, dipyridamole, ASA-ERDP, or ticlopidine for the management of stroke patients.

BACKGROUND: Clinical trials have helped clarify the efficacy of clopidogrel for the treatment and prevention of vascular disease. Costs for its use exceeded $ billion inmaking it the second greatest source of drug expenditure in the world. However, little is. The recent CAPRIE trial (clopidogrel versus aspirin in patients at risk of ischaemic events) compared clopidogrel with aspirin in reducing the risk of vascular events in 19, patients with.

National Institute for Health and Clinical Excellence Centre for Health Technology Evaluation. Pro-forma Response. Executable Model.

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90) The economic model enclosed and its contents are confidential and are.

Abstract. Aspirin and P2Y 12 receptor antagonists are widely used across the spectrum of cardiovascular diseases. Upper gastrointestinal complications, including ulcer and bleeding, are relatively common during antiplatelet treatment and, therefore, concomitant proton pump inhibitor (PPI) treatment is often by: 2.

Aspirin and clopidogrel, alone or together, reduce the rate of cardiovascular events in patients with coronary disease, but their relative cost effectiveness is uncertain. In this study, the use of Cited by: Clopidogrel irreversibly binds to the P2Y12 platelet receptor and acts as a potent inhibitor of platelet activation and aggregation.

It is currently recommended for the prevention of cardiovascular events in patients with acute coronary syndromes, recent ischemic stroke, and peripheral arterial by: 9. 4) not relevant to pharmacogenomics, e.g. genetic diagnostic testing, 5) no economic evaluation, 6) not cardiovascular diseases, 7) intervention not applied to Cited by: 2.